/PRNewswire/ INOVIO (NASDAQ: INO) announced results from the company s novel Phase 1/2 trial of INO-5401 and INO-9012 in combination with PD-1 inhibitor.
CRI Immunotherapy Summit Grows Along with Cancer Treatment Prospects pressreleasepoint.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pressreleasepoint.com Daily Mail and Mail on Sunday newspapers.